HSPD1 and COVID-19: Indeed, it was reported that the HSPD1-derived altered peptide ligand reduced the pro-inflammatory cytokines in rheumatoid arthritis disease and also in COVID-19 patients [48]; in addition, HSPE1 inhibited lipopolysaccharide-induced inflammation by interacting with HSPD1 [49].